Section Arrow
RGNX.NASDAQ
- REGENXBIO
Quotes are at least 15-min delayed:2025/09/12 04:14 EDT
Pre Market
Last
 --
-- (--)
Bid
7.56
Ask
10.3
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 9.49
-0.08 (-0.84%)
Day High 
9.82 
Prev. Close
9.57 
1-M High
10.08 
Volume 
371.09K 
Bid
7.56
Ask
10.3
Day Low
9.145 
Open
9.58 
1-M Low
7.35 
Market Cap 
483.42M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.38 
20-SMA 9.03 
50-SMA 8.71 
52-W High 13.48 
52-W Low 5.035 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.44/-1.47
Enterprise Value
557.55M
Balance Sheet
Book Value Per Share
4.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
83.33M
Operating Revenue Per Share
1.92
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GRIGRI Bio Inc.2.05+0.49+31.41%0.02PE
Pre Market 1.78 -0.27 -13.17%
RXRXRecursion Pharmaceuticals4.85+0.31+6.83%-- 
Pre Market 4.93 +0.08 +1.65%
SLXNSilexion Therapeutics Corp4.93+0.445+9.92%-- 
Pre Market 4.92 -0.01 -0.20%
ADAPAdaptimmune Therapeutics plc0.0505-0.0003-0.59%-- 
Pre Market 0.0515 +0.001 +1.98%
ROIVRoivant Sciences Ltd14.41+0.64+4.65%1.95PE
Pre Market 14.41 0 0.00%
Quotes are at least 15-min delayed:2025/09/12 04:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.